Irinotecan Liposome in Combination With Capecitabine

Pancreatic cancer is a group of malignant tumors mainly originated from pancreatic ductal epithelium and follicular cells, with high degree of malignancy, insidious onset, difficult early diagnosis, rapid progression, short survival time, and one of the malignant tumors with the worst prognosis, which is known as the "king of cancers". In recent years, the incidence rate of pancreatic cancer has been increasing both at home and abroad. At present, the palliative treatment of advanced pancreatic cancer is still mainly based on chemotherapy, such as FOLFIRINOX regimen. And after standard first-l

Trial Details

NCT ID
NCT06578052
Phase
NA
Sponsor
Junjie Hang
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Irinotecan liposome Capecitabine
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • patients were fully aware of the study, participated voluntarily and signed the informed consent form (ICF);
  • aged ≥18 years and ≤80 years;
  • patients with histopathologically confirmed unresectable/metastatic pancreatic cancer;
  • imaging-confirmed tumor progression after prior treatment with a standard first-line regimen;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →